NCAN and cancer: The aim of this prospective study was to determine whether any of a broad range of Neur-Abs (thirteen in total) tested at cancer diagnosis, independent of clinical neurological features, has any impact on survival; the null hypothesis being that none of these antibodies would affect survival.